Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cellectis SA is a biotechnology business based in the US. Cellectis shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectis employs 294 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.69 |
|---|---|
| 52-week range | $2.30 - $15.84 |
| 50-day moving average | $3.31 |
| 200-day moving average | $6.75 |
| Wall St. target price | $13.38 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.95 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.69 from 2022-07-01
| 1 week (2022-06-29) | -6.27% |
|---|---|
| 1 month (2022-06-03) | -17.99% |
| 3 months (2022-04-06) | -40.22% |
| 6 months (2022-01-06) | -66.04% |
| 1 year (2021-07-06) | -81.90% |
|---|---|
| 2 years (2020-07-06) | -85.88% |
| 3 years (2019-07-05) | 16.18 |
| 5 years (2017-07-05) | 25.5 |
| Revenue TTM | $41.4 million |
|---|---|
| Gross profit TTM | $34.2 million |
| Return on assets TTM | -23.35% |
| Return on equity TTM | -58.65% |
| Profit margin | 0% |
| Book value | $4.20 |
| Market capitalisation | $122.4 million |
TTM: trailing 12 months
We're not expecting Cellectis to pay a dividend over the next 12 months.
Over the last 12 months, Cellectis's shares have ranged in value from as little as $2.3 up to $15.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis's is 2.3017. This would suggest that Cellectis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.